person
Stéphane N.
- Country
- France
- Department
- Gastroenterology
Research Overview
assignment
47
Clinical Trials ·
- A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
- One-Year Real-World Effectiveness of Subcutaneous Guselkumab in Adults with Crohn’s Disease
location_city
5
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
473
Sites with multiple studies
Has run more than one trial at 473 of 704 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating inflammatory bowel disease, with particular focus on both Crohn's disease and ulcerative colitis in their moderate to severe forms.
- Treatment of perianal fistulizing Crohn's disease
- Management of postoperative Crohn's disease recurrence
- Bowel urgency control in ulcerative colitis
Therapeutic Innovations
Expertise in evaluating novel therapeutic approaches including biological therapies and small molecule treatments for inflammatory bowel conditions.
- Combination therapy approaches
- Targeted therapeutic agents
- Long-term maintenance treatments
Advanced Treatment Modalities
Focus on innovative treatment methods including fecal microbiota transplantation and treat-to-target strategies for managing intestinal inflammation.
- Microbiome-based interventions
- Endoscopic monitoring approaches
- Therapeutic drug monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.